Penicillin Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Penicillin Market - Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented By Product (Bulk, Dosage), By Type (Aminopenicillin, Antipseudomonal Penicillin, Beta Lactamase Inhibitor, Others), By Route of Administration (Oral, Intramuscular, Intravenous), By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The global penicillin market is projected to expand from USD 10.43 Billion in 2025 to USD 13.21 Billion by 2031, demonstrating a compound annual growth rate (CAGR) of 4.02%. Penicillin, a group of beta-lactam antibiotics derived from Penicillium fungi, is widely used to treat various bacterial infections, including pneumonia, respiratory tract infections, and syphilis. The market's growth is primarily fueled by the increasing prevalence of these infectious diseases, coupled with penicillin's proven clinical effectiveness and its cost-efficiency as a generic treatment. Additionally, the ongoing development of healthcare infrastructure in emerging economies consistently boosts the demand for these vital, life-saving medications, securing their enduring role in therapeutic guidelines independently of short-term market fluctuations.However, the market faces considerable obstacles due to vulnerabilities within its supply chain and the consolidation of manufacturing, which frequently result in drug shortages. This inherent fragility is intensified by the industry's dependence on a limited number of suppliers for active pharmaceutical ingredients (APIs), creating logistical bottlenecks, particularly for older, less profitable drugs. By the third quarter of 2025, the American Society of Health-System Pharmacists reported 214 active drug shortages, highlighting the ongoing instability that impacts the availability of crucial sterile injectables such as penicillin.
Market Driver
The escalating rates of syphilis and other sexually transmitted infections are a primary catalyst for the global penicillin market, creating an urgent need for long-acting injectable formulations like benzathine penicillin G. This specific antibiotic remains the definitive standard for preventing maternal-to-child transmission, making its consistent availability essential as infection rates continue to surpass historical levels. According to the Centers for Disease Control and Prevention's September 2025 'Sexually Transmitted Infections Surveillance, 2024' report, congenital syphilis cases notably rose for the twelfth consecutive year, approaching 4,000 reported incidents, ensuring substantial and consistent procurement from public health organizations, which translates into a stable revenue stream for manufacturers able to meet the stringent sterile manufacturing standards for these critical medications.A second significant driver is the progress in pharmaceutical manufacturing technologies, spurred by government investments aimed at localizing active pharmaceutical ingredient (API) production and enhancing supply chain security. To reduce reliance on foreign suppliers, federal agencies are actively funding domestic infrastructure projects that incorporate continuous manufacturing processes. The U.S. Government Publishing Office's January 2025 '2024 Report to Congress on Increased Manufacturing Capacity for Certain Critical Antibiotic Drugs' disclosed that the Administration for Strategic Preparedness and Response (ASPR) allocated $583 million to Phlow Pharmaceuticals to establish domestic API capabilities, with commercialization targets set for the current fiscal year. These technological upgrades are effectively stabilizing market availability, as evidenced by Republic Pharmaceutical's June 2025 statement that the FDA officially declared the shortage of amoxicillin powder for suspension resolved for four key dosage strengths as of May 2025, reflecting improved industrial capacity.
Market Challenge
Significant supply chain vulnerabilities and concentrated manufacturing pose a critical impediment to the expansion of the global penicillin market. The production of these essential antibiotics relies heavily on a limited number of active pharmaceutical ingredient (API) suppliers, creating a fragile system where a disruption at a single manufacturing site can lead to widespread unavailability. This centralization severely constrains the market's ability to meet escalating global demand, thereby hindering growth as manufacturers struggle to reliably supply crucial sterile injectables to healthcare systems.The economic realities of the sector further complicate this issue, as the low profit margins associated with generic penicillin disincentivize the necessary investments for diversifying supply sources or modernizing outdated infrastructure. This inherent inflexibility results in prolonged periods of scarcity, which undermine market stability. In 2025, the European Association of Hospital Pharmacists reported that approximately 63% of surveyed professionals identified antimicrobial agents as the drug category most frequently affected by critical shortages. Such persistent unreliability compels healthcare providers to resort to alternative therapies, directly diminishing the commercial volume and consistency vital for sustained market development.
Market Trends
Pharmaceutical companies are strategically expanding their portfolios of beta-lactamase inhibitor combinations to counter the growing threat of antimicrobial resistance (AMR). This significant trend involves pairing traditional penicillins with innovative inhibitors, designed to neutralize bacterial defense mechanisms and thus restore the effectiveness of these crucial drugs against resistant strains. The impetus for these advanced formulations is fueled by clinical data indicating high resistance levels in common pathogens, which jeopardizes the efficacy of standard treatments. The UK Health Security Agency's November 2024 'English surveillance of antibiotic prescribing and utilisation report' highlighted that while penicillins remained the most frequently prescribed antibiotic class, Escherichia coli accounted for 65% of all antibiotic-resistant bloodstream infections, underscoring the critical market need for next-generation combination therapies to maintain clinical utility.Concurrently, the industry is witnessing a broad adoption of green enzymatic synthesis, where manufacturers are transitioning from traditional chemical production methods to biocatalytic processes to enhance sustainability. This industrial shift is primarily driven by the imperative to reduce the generation of hazardous waste and decrease energy consumption, aligning with increasingly stringent global environmental regulations. Illustrating the tangible benefits of this technological evolution, Centrient Pharmaceuticals reported in its June 2025 '2024 ESG Report' an 8% reduction in combined Scope 1 and 2 greenhouse gas emissions, a milestone significantly supported by the strategic conversion of its Ramos Arizpe manufacturing facility from chemical synthesis to an environmentally friendly enzymatic process.
Key Market Players
* Astellas Pharma Inc.
* Novartis International AG
* GlaxoSmithKline plc
* Pfizer Inc.
* Merck Co. & Inc.
* F.Hoffmann-La Roche Ltd.
* Toyama Chemical Co., Ltd.
* Sanofi Aventis SA
* MiddleBrook Pharmaceuticals, Inc.
* Gilead Sciences Inc
Report Scope
In this report, the Global Penicillin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Penicillin Market, By Product
* Bulk
* Dosage
# Penicillin Market, By Type
* Aminopenicillin
* Antipseudomonal Penicillin
* Beta Lactamase Inhibitor
* Others
# Penicillin Market, By Route of Administration
* Oral
* Intramuscular
* Intravenous
# Penicillin Market, By End User
* Hospitals & Clinics
* Pharmaceutical & Biotechnology Companies
* Academic & Research Institutions
# Penicillin Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Penicillin Market.
Available Customizations:
Global Penicillin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Penicillin Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Bulk, Dosage)
5.2.2. By Type (Aminopenicillin, Antipseudomonal Penicillin, Beta Lactamase Inhibitor, Others)
5.2.3. By Route of Administration (Oral, Intramuscular, Intravenous)
5.2.4. By End User (Hospitals & Clinics, Pharmaceutical & Biotechnology Companies, Academic & Research Institutions)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Penicillin Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Type
6.2.3. By Route of Administration
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Penicillin Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Type
6.3.1.2.3. By Route of Administration
6.3.1.2.4. By End User
6.3.2. Canada Penicillin Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Type
6.3.2.2.3. By Route of Administration
6.3.2.2.4. By End User
6.3.3. Mexico Penicillin Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Type
6.3.3.2.3. By Route of Administration
6.3.3.2.4. By End User
7. Europe Penicillin Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Type
7.2.3. By Route of Administration
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Penicillin Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Type
7.3.1.2.3. By Route of Administration
7.3.1.2.4. By End User
7.3.2. France Penicillin Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Type
7.3.2.2.3. By Route of Administration
7.3.2.2.4. By End User
7.3.3. United Kingdom Penicillin Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Type
7.3.3.2.3. By Route of Administration
7.3.3.2.4. By End User
7.3.4. Italy Penicillin Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Type
7.3.4.2.3. By Route of Administration
7.3.4.2.4. By End User
7.3.5. Spain Penicillin Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Type
7.3.5.2.3. By Route of Administration
7.3.5.2.4. By End User
8. Asia Pacific Penicillin Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Type
8.2.3. By Route of Administration
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Penicillin Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Type
8.3.1.2.3. By Route of Administration
8.3.1.2.4. By End User
8.3.2. India Penicillin Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Type
8.3.2.2.3. By Route of Administration
8.3.2.2.4. By End User
8.3.3. Japan Penicillin Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Type
8.3.3.2.3. By Route of Administration
8.3.3.2.4. By End User
8.3.4. South Korea Penicillin Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Type
8.3.4.2.3. By Route of Administration
8.3.4.2.4. By End User
8.3.5. Australia Penicillin Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Type
8.3.5.2.3. By Route of Administration
8.3.5.2.4. By End User
9. Middle East & Africa Penicillin Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Type
9.2.3. By Route of Administration
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Penicillin Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Type
9.3.1.2.3. By Route of Administration
9.3.1.2.4. By End User
9.3.2. UAE Penicillin Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Type
9.3.2.2.3. By Route of Administration
9.3.2.2.4. By End User
9.3.3. South Africa Penicillin Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Type
9.3.3.2.3. By Route of Administration
9.3.3.2.4. By End User
10. South America Penicillin Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Type
10.2.3. By Route of Administration
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Penicillin Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Type
10.3.1.2.3. By Route of Administration
10.3.1.2.4. By End User
10.3.2. Colombia Penicillin Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Type
10.3.2.2.3. By Route of Administration
10.3.2.2.4. By End User
10.3.3. Argentina Penicillin Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Type
10.3.3.2.3. By Route of Administration
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Penicillin Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Astellas Pharma Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Novartis International AG
15.3. GlaxoSmithKline plc
15.4. Pfizer Inc.
15.5. Merck Co. & Inc.
15.6. F.Hoffmann-La Roche Ltd.
15.7. Toyama Chemical Co., Ltd.
15.8. Sanofi Aventis SA
15.9. MiddleBrook Pharmaceuticals, Inc.
15.10. Gilead Sciences Inc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們